OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada ; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, RevenirTM. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, RevenirTM. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata , Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our RevenirTM platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About RevenirTM Drug Discovery Platform RevenirTM, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, RevenirTM predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html SOURCE Ono Pharmaceutical co., ltd.Edge Computing Market to Exhibit a Remarkable CAGR of 8.60% by 2032, Size, Share, Trends, Key Drivers, Demand, Opportunity Analysis and Competitive Outlook 11-22-2024 10:24 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research The global edge computing market size was valued at USD 2.33 billion in 2024 and is projected to reach USD 4.51 billion by 2032, with a CAGR of 8.60% during the forecast period of 2025 to 2032. Edge computing is a distributed computing framework that processes data closer to its source, such as at the edge of a network, rather than relying on a centralized data center. This approach reduces latency, enhances real-time data processing, and minimizes bandwidth usage by handling data locally on devices, sensors, or edge servers. Edge computing is particularly valuable in applications that require quick decision-making, such as IoT, autonomous vehicles, smart cities, and industrial automation, where fast and efficient data processing is critical for performance and reliability. Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-edge-computing-market Some of the major players operating in the Edge Computing Market are Nokia (Finland), Huawei Technologies Co. Ltd. (China), Juniper Networks Inc. (U.S.), Dell Inc. (U.S.), Cisco Systems, Inc. (U.S.), Hewlett Packard Enterprise Development LP (U.S.), SixSq SA (Switzerland), eMachineShop (U.S.), SAGUNA (Israel), Vapor IO (U.S.), ADLINK Technology Inc. (U.S.), Amazon Web Services, Inc. (U.S.), GENERAL ELECTRIC (U.S.), IBM (U.S.), Intel Corporation (U.S.), Microsoft (U.S.), SAP SE (Germany) Global Beverage Packaging Market Scope The market is segmented on the basis of component, technology, application, organization size, and vertical. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Component Hardware Gateways Micro Data Center Platform Solution and Services Technology Mobile Edge Computing Fog Computing Application Smart Cities Location Services Analytics Environmental Monitoring Optimized Local Content Data Caching Augmented Reality Others Organization Size Small and Medium-Sized Enterprises Large Enterprises Vertical Manufacturing Healthcare Transportation Government and Public Media and Entertainment Energy and Utilities Telecom and IT Retail Others Browse Trending Reports: https://dbmrblogs02.blogspot.com/2024/11/rig-and-oil-field-market-size-share-and.html https://dbmrblogs02.blogspot.com/2024/11/steel-wire-market-opportunities-and.html https://dbmrblogs02.blogspot.com/2024/11/flow-tank-market-insights-and-growth.html https://dbmrblogs02.blogspot.com/2024/11/polyurea-coating-market-trends-analysis.html About Data Bridge Market Research: An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune. Contact Us: - Data Bridge Market Research Email: - sopan.gedam@databridgemarketresearch.com This release was published on openPR.

Multibillion-dollar plan to convert coal into ‘clean’ hydrogen faltersThe will conclude with a winner-take-all matchup that will determine the path of the NFC playoffs. The league on Sunday night announced the Week 18 schedule, which will wrap up with the hosting the for the NFC North title and the No. 1 seed in the NFC playoffs. The Lions (13-2), who still must play Monday night against the , beat the Vikings (14-2) in , but the rematch will determine the all-important home-field advantage and first-round bye, with the loser being bumped all the way to the No. 5 seed. Saturday will also resolve the AFC North crown, with the hosting the in the afternoon and the , for a wild-card spot, taking on the . Here's the full schedule: Saturday, Jan. 4 Cleveland Browns at Baltimore Ravens, 4:30 p.m. ET, ABC/ESPN Cincinnati Bengals at Pittsburgh Steelers, 8 p.m. ET, ABC/ESPN Sunday, Jan. 5 New York Giants at Philadelphia Eagles, 1 p.m. ET, CBS Buffalo Bills at New England Patriots, 1 p.m. ET, CBS Houston Texans at Tennessee Titans, 1 p.m. ET, CBS Carolina Panthers at Atlanta Falcons, 1 p.m. ET, CBS Washington Commanders at Dallas Cowboys, 1 p.m. ET, FOX Chicago Bears at Green Bay Packers, 1 p.m. ET, FOX Jacksonville Jaguars at Indianapolis Colts, 1 p.m. ET, FOX New Orleans Saints at Tampa Bay Buccaneers, 1 p.m. ET, FOX Kansas City Chiefs at Denver Broncos, 4:25 p.m. ET, CBS Los Angeles Chargers at Las Vegas Raiders, 4:25 p.m., CBS Miami Dolphins at New York Jets, 4:25 p.m., CBS San Francisco 49ers at Arizona Cardinals, 4:25 p.m., CBS Seattle Seahawks at Los Angeles Rams, 4:25 p.m., CBS Minnesota Vikings at Detroit Lions, 8:20 p.m. ET, NBC

NoneAP News in Brief at 6:04 p.m. EST4 analysts have shared their evaluations of Sight Sciences SGHT during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Sight Sciences, presenting an average target of $5.15, a high estimate of $5.50, and a low estimate of $4.60. Observing a downward trend, the current average is 17.86% lower than the prior average price target of $6.27. Breaking Down Analyst Ratings: A Detailed Examination A clear picture of Sight Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joanne Wuensch Citigroup Lowers Neutral $4.60 $5.80 Danielle Antalffy UBS Announces Buy $5.50 - Cecilia Furlong Morgan Stanley Lowers Equal-Weight $5.00 $7.00 Matt O'Brien Piper Sandler Lowers Neutral $5.50 $6.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sight Sciences. This offers insight into analysts' perspectives on the current state of the company. Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sight Sciences compared to the broader market. Price Targets: Gaining insights, analysts provide estimates for the future value of Sight Sciences's stock. This comparison reveals trends in analysts' expectations over time. Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sight Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table. Stay up to date on Sight Sciences analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here . Unveiling the Story Behind Sight Sciences Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. A Deep Dive into Sight Sciences's Financials Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. Positive Revenue Trend: Examining Sight Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.74% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. Net Margin: Sight Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -54.9% net margin, the company effectively manages costs and achieves strong profitability. Return on Equity (ROE): Sight Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.26% ROE, the company effectively utilizes shareholder equity capital. Return on Assets (ROA): Sight Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.55%, the company may encounter challenges in delivering satisfactory returns from its assets. Debt Management: Sight Sciences's debt-to-equity ratio is below the industry average at 0.37 , reflecting a lower dependency on debt financing and a more conservative financial approach. The Basics of Analyst Ratings Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks. Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders. Breaking: Wall Street's Next Big Mover Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details . This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.